Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 1/20 | 0.66 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.66 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.66 |
| ▸ | LPAR1 | Q92633 | 5/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.51 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.50 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.50 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phenylbutanoic Acid SCHEMBL406962 | 0.96 | ADRB2 (0.62) | ADRB2ADRB1ADRB3LPAR1KMT2A | |
| SCHEMBL11293636 | 0.94 | LPAR1 (0.70) | ADRB2ADRB1ADRB3LPAR1KMT2A | |
| SCHEMBL29028798 | 0.94 | LPAR1 (0.70) | ADRB2ADRB1ADRB3LPAR1KMT2A | |
| SCHEMBL9463643 | 0.92 | LPAR1 (0.71) | ADRB2ADRB1ADRB3LPAR1KMT2A | |
| Phenylbutanoic Acid SCHEMBL28794522 | 0.92 | HDAC3 (0.61) | ADRB2ADRB1ADRB3LPAR1KMT2A | |
| SCHEMBL11855276 | 0.86 | ADRB2 (0.52) | ADRB2ADRB1ADRB3LPAR1KMT2A | |
| SCHEMBL8427652 | 0.84 | ADRB2 (0.55) | ADRB2ADRB1ADRB3LPAR1KMT2A | |
| SCHEMBL19300624 | 0.83 | ALDH1A1 (0.53) | ADRB2ADRB1ADRB3LPAR1KMT2A | |
| SCHEMBL31751538 | 0.83 | ALDH1A1 (0.53) | ADRB2ADRB1ADRB3LPAR1KMT2A | |
| SCHEMBL15061844 | 0.82 | MGLL (0.61) | ADRB2ADRB1ADRB3LPAR1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 629 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4649317-A2 | METHODS AND COMPOSITIONS FOR SCREENING AND TREATING ALZHEIMER'S DISEASE | Population Bio, Inc. (US) | 2025-11-19 | — | — | EP | claimed |
| US-12414986-B2 | Use of glutamine synthetase for treating fatty liver disease | THOERIS GMBH (AT) | 2025-09-16 | — | — | US | claimed |
| US-20250228921-A1 | TREATMENT OF ARGINASE 1 DEFICIENCY | IMMEDICA PHARMA AB (SE) | 2025-07-17 | — | — | US | claimed |
| US-12359184-B2 | Use of glutamine synthetase for treating hyperammonemia | THOERIS GMBH (AT) | 2025-07-15 | — | — | US | claimed |
| US-20250101119-A1 | METHODS OF TREATING UREA CYCLE DISORDERS BY INTERFERING WITH GLUCAGON RECEPTOR SIGNALING | REGENERON PHARMA (US) | 2025-03-27 | — | — | US | claimed |
| US-20250073318-A1 | MITAPIVAT THERAPY AND MODULATORS OF CYTOCHROME P450 | AGIOS PHARMACEUTICALS, INC. | 2025-03-06 | — | — | US | claimed |
| US-20250000829-A1 | PHENYLBUTYRATE COMPOSITIONS FOR TREATING DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY (“DEE”), AND STXBP1 DISORDERS | CORNELL UNIVERSITY (US) | 2025-01-02 | — | — | US | claimed |
| US-12139546-B2 | Methods of treating urea cycle disorders by interfering with glucagon receptor signaling | REGENERON PHARMACEUTICALS, INC. (US) | 2024-11-12 | — | — | US | claimed |
| WO-2024194181-A1 | NH3 SCAVENGER FOR USE IN THE TREATMENT OF MOBILITY DISABILITY IN A POST-STROKE PATIENT | Merz Therapeutics GmbH (DE) | 2024-09-26 | — | — | WO | claimed |
| US-20240310389-A1 | METHODS AND COMPOSITIONS FOR SCREENING AND TREATING ALZHEIMER'S DISEASE | POPULATION BIO INC (US) | 2024-09-19 | — | — | US | claimed |
| WO-2016085887-A1 | TREATMENT OF DISEASES ASSOCIATED WITH HEPATIC STELLATE CELL ACTIVATION USING AMMONIA-LOWERING THERAPIES | UCL BUSINESS PLC (GB) | 2016-06-02 | — | — | WO | claimed |
| EP-3013372-A1 | METHODS FOR TREATING UREA CYCLE DISORDERS TO PREVENT HYPERAMMONEMIC CRISES BY CONTROLLING BLOOD AMMONIA LEVELS | Horizon Therapeutics, Inc. (US) | 2016-05-04 | — | — | EP | claimed |
| US-9226965-B2 | Method and composition for treating heart failure | U.S. DEPARTMENT OF VETERANS AFFAIRS (US) | 2016-01-05 | — | — | US | claimed |
| WO-2015187641-A1 | METHODS FOR TREATING UREA CYCLE DISORDERS TO PREVENT HYPERAMMONEMIC CRISES BY CONTROLLING BLOOD AMMONIA LEVELS | HORIZON THERAPEUTICS, INC. (US) | 2015-12-10 | — | — | WO | claimed |
| WO-2015073816-A1 | SOLID COMPOSITIONS OF TRIGLYCERIDES AND USES THEREOF | ULTRAGENYX PHARMACEUTICAL INC. (US) | 2015-05-21 | — | — | WO | claimed |
| US-20150087703-A1 | COMPOSITION AND METHOD FOR TREATING NEURODEGENERATIVE DISEASE | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2015-03-26 | — | — | US | claimed |
| US-20140206763-A1 | PHENYLBUTYRATE FOR TREATMENT OF SPORADIC INCLUSION-BODY MYOSITIS AND DISORDERS RELATING TO AUTOPHAGY IMPAIRMENT OR AMYLOID BETA 42 ACCUMULATION | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2014-07-24 | — | — | US | claimed |
| WO-2013149091-A1 | COMPOSITION AND METHOD FOR TREATING NEURODEGENERATIVE DISEASE | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2013-10-03 | — | — | WO | claimed |
| WO-2009048540-A1 | METHOD AND COMPOSITION FOR TREATING HEART FAILURE | U.S. DEPARTMENT OF VETERANS AFFAIRS OFFICE OF GENERAL COUNSEL - PSG IV (024) (US) | 2009-04-16 | — | — | WO | claimed |
| US-20090093535-A1 | Method and composition for treating heart failure | U.S. DEPARTMENT OF VETERANS AFFAIRS (US) | 2009-04-09 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140206763-A1 | PHENYLBUTYRATE FOR TREATMENT OF SPORADIC INCLUSION-BODY MYOSITIS AND DISORDERS RELATING TO AUTOPHAGY IMPAIRMENT OR AMYLOID BETA 42 ACCUMULATION | GOLT1B, MAP1LC3B, VCP | ADRB2 1657/4885ADRB1 1067/4885ADRB3 1061/4885 |
| US-20250073318-A1 | MITAPIVAT THERAPY AND MODULATORS OF CYTOCHROME P450 | PKM, PDK1, PKD2 | ADRB2 1795/4885ADRB1 1317/4885ADRB3 1520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.